The present disclosure is directed to antibodies binding to and neutralizing Japanese Encephalitis virus and methods for use thereof.

A system and method for automated single cell capture and processing is described, where the system includes a deck supporting and positioning a set of sample processing elements (including an integrated imaging subsystem); a gantry for actuating tools for interactions with the set of sample processing elements supported by the deck; and a base supporting various processing subsystems and a control subsystems in communication with the processing subsystems. The system can automatically execute workflows associated with single cell processing, including antibody detection, other protein detection, mRNA detection, and/or other applications associated with spatial transcriptomics.

This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.

The present invention provides a composition and a combined medication method for treating an enterovirus infection. In particular, the present invention provides a composition for inhibiting enteroviruses, wherein the composition at least contains an inhibitor of a 3D virus protein and an inhibitor of a capsid protein, or a combination of an inhibitor of a 3C protein and an inhibitor of a 3A protein.

A method for making and a resultant paper test strip product for detecting Zika antibodies indicating the presence of Zika virus in a patient sample. The paper test strip includes a strip of filter paper; and a silk fibroin solution applied to the strip of filter paper wherein the silk fibroin solution is mixed with an enzyme solution in phosphate buffered saline buffer.

A method of analyzing biological data containing expression values of a plurality of polypeptides in the blood of a subject. The method comprises: calculating a distance between a segment of a curved line and an axis defined by a direction, the distance being calculated at a point over the curved line defined by a coordinate along the direction. The method further comprises correlating the distance to the presence of, absence of, or likelihood that the subject has, a bacterial infection. The coordinate is defined by a combination of the expression values, wherein at least 90% of the segment is between a lower bound line and an upper bound line.

A recombinant or chemically synthesized polypeptide includes SEQ ID NO: 1 or a variant thereof. A diagnostically useful carrier includes means for specifically capturing an antibody to SEQ ID NO: 1 in a sample from a subject. A kit includes the polypeptide or the diagnostically useful carrier. A method for diagnosing, proposing, or monitoring the treatment of a virus, preferably Flavivirus, more preferably POWV infection includes detecting in the sample from a subject the presence or absence of an antibody to SEQ ID NO: 1 and/or an antibody to SEQ ID NO: 2. A polypeptide including SEQ NO: 1 and/or SEQ ID NO: 2, and/or a variant thereof is useful for the diagnosis. An IgIVI antibody to SEQ ID NO: 1 or means for specifically capturing an IgM class antibody to SEQ ID NO: 1 is useful for increasing the diagnostic reliability of an immunoassay for the diagnosis of a virus infection.

A system and method for using new biomarkers to assess individual diseases, including, but not limited to, a patient's prognosis before and/or after being diagnosed with the disease. In one embodiment of the present invention, absolute quantification of annotated metabolites by mass spectrometry is used to identify certain biomarkers and derivatives thereof (i.e., signatures), which are then used to screen for, diagnose, predict, prognose, and/or treat various diseases, including, but not limited to, COVID-19.

This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.

This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.